Washington 2019-2020 Regular Session Status: Passed House Bipartisan · 17 D · 3 R cosponsors

HB 1331 — Concerning opioid use disorder treatment, prevention, and related services.

Last action — House Rules "X" file.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2019-2020 Regular Session. It reached “Passed House” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

In plain language

The bill addresses opioid use disorder treatment and prevention measures in Washington State.

This bill aims to tackle opioid use disorder by improving access to treatment, enhancing service coordination, and promoting prevention. It mandates healthcare providers to inform patients of their right to refuse opioid prescriptions.

What this means for you
  • Workers: Healthcare workers will need to educate patients on their rights regarding opioid prescriptions.

Bill Text

What changed in the latest version

2 added · 2 removed

Plain-language change summary

The amendment to Bill HB 1331 introduces several key updates aimed at enhancing the treatment and prevention of opioid use disorder in Washington State. Notably, new provisions require healthcare providers, including podiatrists, dentists, and others who prescribe opioids, to inform patients of their right to refuse such prescriptions, thereby promoting informed patient choice. Additionally, the legislation now mandates the development of a coordinated plan for distributing opioid overdose reversal medications across the state, emphasizing a proactive approach to reducing opioid-related harm. These changes are significant as they aim to foster better patient education, improve access to treatment, and ultimately address the ongoing opioid crisis more effectively.

→
Previous
Latest
H-2221.1SECOND SUBSTITUTE HOUSE BILL 1331State of Washington66th Legislature2019 Regular SessionByHouse Appropriations (originally sponsored by Representatives Cody, Caldier, Harris, Stonier, Peterson, Irwin, Macri, Mosbrucker, Jinkins, Kilduff, Appleton, Ryu, Davis, Robinson, Eslick, Lekanoff, Thai, Tharinger, Walen, Bergquist, Kloba, Leavitt, Ormsby, Pollet, and Wylie;
Z-0420.1HOUSE BILL 1331State of Washington66th Legislature2019 Regular SessionByRepresentatives Cody, Caldier, Harris, Stonier, Peterson, Irwin, Macri, Mosbrucker, Jinkins, Kilduff, Appleton, Ryu, Davis, Robinson, Eslick, Lekanoff, Thai, Tharinger, Walen, Bergquist, Kloba, Leavitt, Ormsby, Pollet, and Wylie;
by request of Office of the Governor)READ FIRST TIME 03/01/19.AN ACT Relating to opioid use disorder treatment, prevention, and related services;
by request of Office of the GovernorRead first time 01/18/19.Referred to Committee on Health Care & Wellness.AN ACT Relating to opioid use disorder treatment, prevention, and related services;
amending RCW 69.41.055, 69.41.095, 70.41.480, 70.168.090, 70.225.010, 70.225.040, 71.24.011, 71.24.560, 71.24.585, 71.24.590, and 71.24.595;
amending RCW 69.41.055, 69.41.095, 70.41.480, 70.168.090, 70.225.010, 70.225.040, 71.24.011, 71.24.560, 2.30.030, 71.24.585, 71.24.590, and 71.24.595;
reenacting and amending RCW 69.50.312, 69.50.312, 70.225.020, and 71.24.580;
reenacting and amending RCW 69.50.312, 70.225.020, and 71.24.580;
creating new sections;
and creating a new section.BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:NEW SECTION.  Sec.
providing an effective date;
and providing an expiration date.BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:NEW SECTION.  Sec.
It does not include intentional administration via the intravenous route.(c) "Opioid-related overdose" means a condition including, but not limited to, ((extreme physical illness,)) decreased level of consciousness, nonresponsiveness, respiratory depression, coma, or death that:
It does not include intentional administration via the intravenous route.(c) "Opioid-related overdose" means a condition including, but not limited to, extreme physical illness, decreased level of consciousness, respiratory depression, coma, or death that:
and(f) The pharmacist shall exercise professional judgment regarding the accuracy, validity, and authenticity of the prescription drug order received by way of electronic transmission, consistent with federal and state laws and rules and guidelines of the commission.(2) The commission may adopt rules implementing this section.Sec.
and(f) The pharmacist shall exercise professional judgment regarding the accuracy, validity, and authenticity of the prescription drug order received by way of electronic transmission, consistent with federal and state laws and rules and guidelines of the commission.(2) The commission may adopt rules implementing this section.NEW SECTION.  Sec.
RCW 69.50.312 and 2013 c 276 s 4 and 2013 c 19 s 105 are each reenacted and amended to read as follows:(1) Information concerning a prescription for a controlled substance included in Schedules II through V, or information concerning a refill authorization for a controlled substance included in Schedules III through V(([,] may)), must be electronically communicated to a pharmacy of the patient's choice pursuant to the provisions of this chapter if the electronically communicated prescription information complies with the following:(a) Electronically communicated prescription information must comply with all applicable statutes and rules regarding the form, content, recordkeeping, and processing of a prescription for a legend drug;(b) ((The system used for transmitting electronically communicated prescription information must be approved by the commission and in accordance with federal rules for electronically communicated prescriptions for controlled substance[s] included in Schedules II through V, as set forth in Title 21 C.F.R.
Parts 1300, 1304, 1306, and 1311.
This subsection does not apply to currently used facsimile equipment transmitting an exact visual image of the prescription.
The commission shall maintain and provide, upon request, a list of systems used for electronically communicating prescription information currently approved by the commission;(c) An explicit opportunity for practitioners must be made to indicate their preference on whether a therapeutically equivalent generic drug may be substituted;(d))) Prescription drug orders ((are confidential health information, and)) may be released only to the patient or the patient's authorized representative, the prescriber or other authorized practitioner then caring for the patient, or other persons specifically authorized by law to receive such information;(((e) To maintain confidentiality of prescription records, the electronic system shall have adequate security and systems safeguards designed to prevent and detect unauthorized access, modification, or manipulation of these records.
The pharmacist in charge shall establish or verify the existence of policies and procedures which ensure the integrity and confidentiality of prescription information transmitted to the pharmacy by electronic means.
All managers, employees, and agents of the pharmacy are required to read, sign, and comply with the established policies and procedures;
and(f)))(c) The pharmacist shall exercise professional judgment regarding the accuracy, validity, and authenticity of the prescription drug order received by way of electronic transmission, consistent with federal and state laws and rules and guidelines of the commission.(2) ((The commission may adopt rules implementing this section.))The following are exempt from subsection (1) of this section:(a) Prescriptions issued by veterinarians, as that practice is defined in RCW 18.92.010;(b) Prescriptions issued for a patient of a long-term care facility as defined in RCW 18.64.011, or a hospice program as defined in RCW 18.64.011;(c) When the electronic system used for the communication of prescription information is unavailable due to a temporary technological or electronic failure;(d) Prescriptions issued that are intended for prescription fulfilment and dispensing outside Washington state;(e) When the prescriber and pharmacist are employed by the same entity, or employed by entities under common ownership or control;(f) Prescriptions issued for a drug that the United States food and drug administration or the United States drug enforcement administration requires to contain certain elements that are not able to be accomplished electronically;(g) Any controlled substance prescription that requires compounding as defined in RCW 18.64.011;(h) Prescriptions issued for the dispensing of a nonpatient specific prescription under a standing order, approved protocol for drug therapy, collaborative drug therapy agreement, in response to a public health emergency, or other circumstances allowed by statute or rule where a practitioner may issue a nonpatient specific prescription;(i) Prescriptions issued under a drug research protocol;(j) Prescriptions issued by a practitioner with the capability of electronic communication of prescription information under this section, when the practitioner reasonably determines it is impractical for the patient to obtain the electronically communicated prescription in a timely manner, and such delay would adversely impact the patient's medical condition;
or(k) Prescriptions issued by a prescriber who has received a waiver from the department.(3) The department must develop a waiver process for the requirements of subsection (1) of this section for practitioners due to economic hardship, technological limitations that are not reasonably in the control of the practitioner, or other exceptional circumstance demonstrated by the practitioner.
The waiver must be limited to one year or less, or for any other specified time frame set by the department.(4) A pharmacist who receives a written, oral, or faxed prescription is not required to verify that the prescription properly meets any exemptions under this section.
Pharmacists may continue to dispense and deliver medications from otherwise valid written, oral, or faxed prescriptions.(5) An individual who violates this section commits a civil violation.
Disciplinary authorities may impose a fine of two hundred fifty dollars per violation, not to exceed five thousand dollars per calendar year.
Fines imposed under this section must be allocated to the health professions account.(6) Systems used for the electronic communication of prescription information must:(a) Comply with federal laws and rules for electronically communicated prescriptions for controlled substances included in Schedules II through V, as required by Title 21 C.F.R.
parts 1300, 1304, 1306, and 1311;(b) Meet the national council for prescription drug prescriber/pharmacist interface SCRIPT standard as determined by the department in rule;(c) Have adequate security and systems safeguards designed to prevent and detect unauthorized access, modification, or manipulation of these records;(d) Provide an explicit opportunity for practitioners to indicate their preference on whether a therapeutically equivalent generic drug may be substituted;
and(e) Include the capability to input and track partial fills of a controlled substance prescription in accordance with section 7 of this act.NEW SECTION.  Sec.
17.
18.
17.
or(c) When, in the judgment of the practitioner and consistent with hospital policies and procedures, a patient is at risk of opioid overdose and the prepackaged emergency medication being distributed is an opioid overdose reversal medication.
or(c) When, in the judgment of the practitioner and consistent with hospital policies and procedures, a patient is at risk of opioid overdose and the prepackaged emergency medication being distributed is an opioid overdose reversal medication.(3) A hospital may only allow this practice if:
The labeling requirements of RCW 69.41.050 and 18.64.246 do not apply to opioid overdose reversal medications dispensed, distributed, or delivered pursuant to a prescription, collaborative drug therapy agreement, standing order, or protocol issued in accordance with this section.
The individual or entity that dispenses, distributes, or delivers an opioid overdose reversal medication as authorized by this section must ensure that directions for use are provided.(3) A hospital may only allow this practice if:
19.
18.
The data collected must include data on suspected drug overdoses for the purposes of including, but not limited to, identifying individuals to engage substance use disorder peer professionals, patient navigators, outreach workers, and other professionals as appropriate to prevent further overdoses and to induct into treatment and provide other needed supports as may be available.(3) In each emergency medical services and trauma care planning and service region, a regional emergency medical services and trauma care systems quality assurance program shall be established by those facilities authorized to provide levels I, II, and III trauma care services.
The data collected must include data on suspected drug overdoses for the purposes of including, but not limited to, identifying individuals to engage substance use disorder peer professionals to prevent further overdoses and to induct into treatment and provide other needed supports as may be available.(3) In each emergency medical services and trauma care planning and service region, a regional emergency medical services and trauma care systems quality assurance program shall be established by those facilities authorized to provide levels I, II, and III trauma care services.
20.
19.
21.
20.
and(f) Dispenser.(3)(a) Until January 1, 2021, each dispenser shall submit the information in accordance with transmission methods established by the department, not later than one business day from the date of dispensing or at the interval required by the department in rule, whichever is sooner.(b) Beginning January 1, 2021, each dispenser must submit the information as soon as readily available, but no later than one business day from the date of distributing, and in accordance with transmission methods established by the department.(4) The data submission requirements of subsections (1) through (3) of this section do not apply to:(a) Medications provided to patients receiving inpatient services provided at hospitals licensed under chapter 70.41 RCW;
and(f) Dispenser.(3) Each dispenser shall submit the information in accordance with transmission methods established by the department, not later than one business day from the date of dispensing or at the interval required by the department in rule, whichever is sooner.(4) The data submission requirements of subsections (1) through (3) of this section do not apply to:(a) Medications provided to patients receiving inpatient services provided at hospitals licensed under chapter 70.41 RCW;
22.
21.
and(e) Assess improvements to the prescription monitoring program to establish a modality to identify patients that do not wish to receive opioid medications in a manner that allows an ordering or prescribing physician to be able to use the prescription monitoring program to identify patients who do not wish to receive opioids or patients that have had an opioid-related overdose.(2) By January 1, 2021, a facility, entity, office, or provider group identified in RCW 70.225.040 with ten or more providers that is not a critical access hospital as defined in RCW 74.60.010 that uses a federally certified electronic health records system must demonstrate that the facility's or entity's federally certified electronic health record is able to fully integrate data to and from the prescription monitoring program using a mechanism approved by the department under subsection (3) of this section.(3) Electronic health record system vendors who are fully integrated with the prescription monitoring program in Washington state may not charge an ongoing fee or a fee based on the number of transactions or providers.
and(e) Assess improvements to the prescription monitoring program to establish a modality to identify patients that do not wish to receive opioid medications in a manner that allows an ordering or prescribing physician to be able to use the prescription monitoring program to identify patients who do not wish to receive opioids or patients that have had an opioid-related overdose.(2) By July 1, 2020, a facility or entity identified in RCW 70.225.040 with ten or more providers that is not a critical access hospital as defined in RCW 74.60.010 that uses a federally certified electronic health records system must demonstrate that the facility's or entity's federally certified electronic health record is able to fully integrate data to and from the prescription monitoring program using a mechanism approved by the department under subsection (3) of this section.(3) Electronic health record system vendors who are fully integrated with the prescription monitoring program in Washington state may not charge an ongoing fee or a fee based on the number of transactions or providers.
For the purposes of this subsection, "fully integrated" means that the electronic health records system must:(a) Send information to the prescription monitoring program without provider intervention using a mechanism approved by the department;(b) Make current information from the prescription monitoring program available to a provider within the workflow of the electronic health records system;
For the purposes of this subsection, "fully integrated" means that the electronic health records system must:(a) Send information to the prescription monitoring program without physician intervention using one of the standard transmission and content standards supported by the state health information exchange for all controlled substances;(b) Make current information from the prescription monitoring program available to a provider within the workflow of the electronic health records system;
23.
22.
and(iii) Administration and enforcement of this chapter or chapter 69.50 RCW;(((k)))(j) Personnel of a test site that meet the standards under RCW 70.225.070 pursuant to an agreement between the test site and a person identified in (a) of this subsection to provide assistance in determining which medications are being used by an identified patient who is under the care of that person;(((l)))(k) A health care facility or entity for the purpose of providing medical or pharmaceutical care to the patients of the facility or entity, or for quality improvement purposes if((:(i)))the facility or entity is licensed by the department or is licensed or certified under chapter 71.24, 71.34, or 71.05 RCW or is an entity deemed for purposes of chapter 71.24 RCW to meet state minimum standards as a result of accreditation by a recognized behavioral health accrediting body, or is operated by the federal government or a federally recognized Indian tribe;
and(iii) Administration and enforcement of this chapter or chapter 69.50 RCW;(((k)))(j) Personnel of a test site that meet the standards under RCW 70.225.070 pursuant to an agreement between the test site and a person identified in (a) of this subsection to provide assistance in determining which medications are being used by an identified patient who is under the care of that person;(((l)))(k) A health care facility or entity for the purpose of providing medical or pharmaceutical care to the patients of the facility or entity, or for quality improvement purposes if:(i) The facility or entity is licensed by the department or is licensed or certified under chapter 71.24, 71.34, or 71.05 RCW or is an entity deemed for purposes of chapter 71.24 RCW to meet state minimum standards as a result of accreditation by a recognized behavioral health accrediting body, or is operated by the federal government or a federally recognized Indian tribe;
((and(ii) The facility or entity is a trading partner with the state's health information exchange;(m)))(l) A health care provider group of five or more ((providers))prescribers or dispensers for purposes of providing medical or pharmaceutical care to the patients of the provider group, or for quality improvement purposes if((:(i)))all the ((providers))prescribers or dispensers in the provider group are licensed by the department or the provider group is operated by the federal government or a federally recognized Indian tribe;
and(ii) The facility or entity is a trading partner with the state's health information exchange;(((m)))(l) A health care provider group of five or more ((providers))prescribers or dispensers for purposes of providing medical or pharmaceutical care to the patients of the provider group, or for quality improvement purposes if:(i) All the ((providers))prescribers or dispensers in the provider group are licensed by the department or the provider group is operated by the federal government or a federally recognized Indian tribe;
((and(ii) The provider group is a trading partner with the state's health information exchange;(n)))(m) The local health officer of a local health jurisdiction for the purposes of patient follow-up and care coordination following a controlled substance overdose event.
and(ii) The provider group is a trading partner with the state's health information exchange;(((n)))(m) The local health officer of a local health jurisdiction for the purposes of patient follow-up and care coordination following a controlled substance overdose event.
Show all 79 changed rows (39 more)
Previous
Latest
Direct and indirect patient identifiers may be provided for research that has been approved by the Washington state institutional review board and by the department through a data-sharing agreement.(b)(i) The department may provide dispenser and prescriber data and data that includes indirect patient identifiers to the Washington state hospital association for use solely in connection with its coordinated quality improvement program maintained under RCW 43.70.510 after entering into a data use agreement as specified in RCW 43.70.052(8) with the association.
Indirect patient identifiers may be provided for research that has been approved by the Washington state institutional review board and by the department through a data-sharing agreement.(b)(i) The department may provide dispenser and prescriber data and data that includes indirect patient identifiers to the Washington state hospital association for use solely in connection with its coordinated quality improvement program maintained under RCW 43.70.510 after entering into a data use agreement as specified in RCW 43.70.052(8) with the association.
The department may provide dispenser and prescriber data and data that includes indirect patient identifiers to the Washington state medical association for use solely in connection with its coordinated quality improvement program maintained under RCW 43.70.510 after entering into a data use agreement with the association.(ii) The department may provide data including direct and indirect patient identifiers to the department of social and health services office of research and data analysis, the department of labor and industries, and the health care authority for research that has been approved by the Washington state institutional review board and, with a data-sharing agreement approved by the department, for public health purposes to improve the prevention or treatment of substance use disorders.(iii) The department may provide a prescriber feedback report to the largest health professional association representing each of the prescribing professions.
The department may provide dispenser and prescriber data and data that includes indirect patient identifiers to the Washington state medical association for use solely in connection with its coordinated quality improvement program maintained under RCW 43.70.510 after entering into a data use agreement with the association.(ii) The department may provide data including direct and indirect patient identifiers to the department of social and health services office of research and data analysis for research that has been approved by the Washington state institutional review board and, with a data-sharing agreement approved by the department, for public health purposes to improve the prevention or treatment of substance use disorders.(iii) The department may provide a prescriber feedback report to the largest health professional association representing each of the prescribing professions.
The health professional associations must distribute the feedback report to prescribers engaged in the professions represented by the associations for quality improvement purposes, so long as the reports contain no direct patient identifiers that could be used to identify individual patients, dispensers, and persons who received prescriptions from dispensers, and the association enters into a written data-sharing agreement with the department.
The health professional associations must distribute the feedback report to prescribers engaged in the professions represented by the associations for quality improvement purposes, so long as the reports contain no direct or indirect patient identifiers that could be used to identify individual patients, dispensers, and persons who received prescriptions from dispensers, and the association enters into a written data-sharing agreement with the department.
24.
23.
25.
24.
26.
25.
27.
26.
The submitted plan should incorporate current evidence-based practices in substance use disorder treatment.
The funds shall be used solely to provide approved alcohol and substance abuse treatment pursuant to RCW 71.24.560 and treatment support services.
The funds shall be used solely to provide approved alcohol and substance ((abuse))use disorder treatment pursuant to RCW 71.24.560 and treatment support services.
No more than ten percent of the total moneys received under subsections (4) and (5) of this section by a county or group of counties participating in a regional agreement shall be spent for treatment support services.(7) Counties are encouraged to consider regional agreements and submit regional plans for the efficient delivery of treatment under this section.(8) Moneys allocated under this section shall be used to supplement, not supplant, other federal, state, and local funds used for substance abuse treatment.(9) If a region or county uses criminal justice treatment account funds to support a therapeutic court, the therapeutic court must allow the use of medication-assisted treatment when deemed medically appropriate for a participant.
No more than ten percent of the total moneys received under subsections (4) and (5) of this section by a county or group of counties participating in a regional agreement shall be spent for treatment support services.(7) Counties are encouraged to consider regional agreements and submit regional plans for the efficient delivery of treatment under this section.(8) Moneys allocated under this section shall be used to supplement, not supplant, other federal, state, and local funds used for substance abuse treatment.(9) If a region or county uses criminal justice treatment account funds to support a therapeutic court, the therapeutic court must allow the use of all medications approved by the federal food and drug administration for the treatment of opioid use disorder as deemed medically appropriate for a participant by a medical professional.
All Washington state therapeutic courts must implement the national association of drug court professionals best practice standards to the extent that their jurisdiction has access to the necessary treatment and recovery support resources to enable implementation.
If appropriate medication-assisted treatment resources are not available or accessible within the jurisdiction, the health care authority's designee for assistance must assist the court with acquiring the resource.(10) Counties must meet the criteria established in RCW 2.30.030(3).Sec.
If appropriate treatment and recovery support resources are not available, courts must contact the authority's designee for assistance with acquiring the resource.
Each court must have all ten best practice standards implemented in their court by June 30, 2020.
The authority must submit a report by December 1, 2020, to the legislature on the progress of the best practice implementation throughout all of the therapeutic courts in the state.(10) Counties must meet the criteria established in RCW 2.30.030(3).Sec.
27.
RCW 2.30.030 and 2018 c 201 s 9002 are each amended to read as follows:(1) Every trial and juvenile court in the state of Washington is authorized and encouraged to establish and operate therapeutic courts.
Therapeutic courts, in conjunction with the government authority and subject matter experts specific to the focus of the therapeutic court, develop and process cases in ways that depart from traditional judicial processes to allow defendants or respondents the opportunity to obtain treatment services to address particular issues that may have contributed to the conduct that led to their arrest or involvement in the child welfare system in exchange for resolution of the case or charges.
In criminal cases, the consent of the prosecutor is required.(2) While a therapeutic court judge retains the discretion to decline to accept a case into the therapeutic court, and while a therapeutic court retains discretion to establish processes and determine eligibility for admission to the therapeutic court process unique to their community and jurisdiction, the effectiveness and credibility of any therapeutic court will be enhanced when the court implements evidence-based practices, research-based practices, emerging best practices, or promising practices that have been identified and accepted at the state and national levels.
Promising practices, emerging best practices, and/or research-based programs are authorized where determined by the court to be appropriate.
As practices evolve, the trial court shall regularly assess the effectiveness of its program and the methods by which it implements and adopts new best practices.(3) Except under special findings by the court, the following individuals are not eligible for participation in therapeutic courts:(a) Individuals who are currently charged or who have been previously convicted of a serious violent offense or sex offense as defined in RCW 9.94A.030;(b) Individuals who are currently charged with an offense alleging intentional discharge, threat to discharge, or attempt to discharge a firearm in furtherance of the offense;(c) Individuals who are currently charged with or who have been previously convicted of vehicular homicide or an equivalent out-of- state offense;
or(d) Individuals who are currently charged with or who have been previously convicted of:
An offense alleging substantial bodily harm or great bodily harm as defined in RCW 9A.04.110, or death of another person.(4) Consistent with RCW 71.24.580(9), any jurisdiction ((establishing))that has established or is establishing a therapeutic court ((shall endeavor to))must incorporate the ((therapeutic court principles of best practices as))national association of drug court professionals best practice standards to the extent that the jurisdiction has access to the necessary treatment and recovery support resources to enable implementation.
If appropriate treatment and recovery support resources are not available, courts must contact a health care authority's designee for assistance with acquiring the resource.
The national association of drug court professionals best practice standards are recognized by state and national therapeutic court organizations in structuring a particular program, which may include:(a) Determining the population;(b) Performing a clinical assessment;(c) Developing the treatment plan;(d) Monitoring the participant, including any appropriate testing;(e) Forging agency, organization, and community partnerships;(f) Taking a judicial leadership role;(g) Developing case management strategies;(h) Addressing transportation, housing, and subsistence issues;(i) Evaluating the program;(j) Ensuring a sustainable program.(5) Upon a showing of indigence under RCW 10.101.010, fees may be reduced or waived.(6) The health care authority shall furnish services to therapeutic courts addressing dependency matters where substance abuse or mental health are an issue unless the court contracts with providers outside of the health care authority.(7) Any jurisdiction that has established more than one therapeutic court under this chapter may combine the functions of these courts into a single therapeutic court.(8) Nothing in this section prohibits a district or municipal court from ordering treatment or other conditions of sentence or probation following a conviction, without the consent of either the prosecutor or defendant.(9) No therapeutic or specialty court may be established specifically for the purpose of applying foreign law, including foreign criminal, civil, or religious law, that is otherwise not required by treaty.(10) No therapeutic or specialty court established by court rule shall enforce a foreign law, if doing so would violate a right guaranteed by the Constitution of this state or of the United States.Sec.
It is also recognized that many individuals have multiple substance use disorders, as well as histories of trauma, developmental disabilities, or mental health conditions.
It is also recognized that many individuals have multiple substance use disorders, co-occurring behavioral health conditions, or histories of trauma.
As such, all individuals experiencing opioid use disorder should be offered evidence-supported treatments to include federal food and drug administration approved medications for the treatment of opioid use disorders and behavioral counseling and social supports to address them.
As such, all individuals experiencing opioid use disorder should be assessed for co-occurring disorders and history of trauma, and offered evidence-supported treatments to include behavioral counseling and social supports to address them.
It is the intent of the legislature that through a strong collaborative care approach, involving the team of providers, the person with opioid use disorder should be provided with a well-coordinated plan of interventions based on evidence while preserving the patient voice in treatment.
Through a strong collaborative care approach, involving the team of providers, the person with opioid use disorder must be provided with a well-coordinated plan of interventions based on evidence while preserving the patient voice in treatment.
Providers must inform patients with opioid use disorder or substance use disorder of options to access federal food and drug administration approved medications for the treatment of opioid use disorder or substance use disorder.
Providers must inform patients of all evidence-based treatment options available.
and(b) Soliciting and receiving private funds, grants, and donations from any willing person or entity.(6)(a) The authority may replicate effective approaches such as opioid hub and spoke treatment networks to broaden outreach and patient navigation with allied opioid use disorder community partners, including but not limited to:
and(b) Soliciting and receiving private funds, grants, and donations from any willing person or entity.(6)(a) The authority shall replicate effective approaches such as opioid hub and spoke treatment networks to broaden outreach and patient navigation with allied opioid use disorder community partners, including but not limited to:
A new section is added to chapter 71.24 RCW to read as follows:(1) Subject to funds appropriated by the legislature, or approval of a section 1115 demonstration waiver from the federal centers for medicare and medicaid services, to fund opioid treatment medications for persons eligible for medicaid at or during the time of incarceration and juvenile detention facilities, the authority shall establish a methodology for distributing funds to city and county jails to provide medication for the treatment of opioid use disorder to individuals in the custody of the facility in any status.
A new section is added to chapter 71.24 RCW to read as follows:(1) By January 1, 2021, city and county jails in Washington must adopt requirements for addressing the behavioral health needs of incarcerated individuals with an opioid use disorder, in accordance with chapter 70.48 RCW.
The authority must prioritize funding for the services required in (a) of this subsection.
These requirements must be adopted, as failure to treat opioid use disorder during incarceration has serious consequences, including an extremely high risk of overdose death after release, and high rates of crime and recidivism correlated with untreated opioid use disorder during incarceration.
To the extent that funding is provided, city and county jails must:(a) Provide medication for the treatment of opioid use disorder to individuals in the custody of the facility, in any status, who were receiving medication for the treatment of opioid use disorder through a legally authorized medical program or by a valid prescription immediately before incarceration;
City and county jail requirements must include developing policies and practices that:(a) Provide medication for the treatment of opioid use disorder to individuals in the custody of the facility, in any status, who were receiving medication for the treatment of opioid use disorder through a legally authorized medical program or by a valid prescription immediately before incarceration;(b) Provide medication for the treatment of opioid use disorder to incarcerated individuals not less than thirty days before release when treatment is determined to be medically appropriate by a health care practitioner;
and(b) Provide medication for the treatment of opioid use disorder to incarcerated individuals not less than thirty days before release when treatment is determined to be medically appropriate by a health care practitioner.
and(c) Make every possible effort to directly connect incarcerated individuals receiving medication for the treatment of opioid use disorder to an appropriate provider or treatment site in the geographic region in which the individual will reside before release.
(2) City and county jails must make reasonable efforts to directly connect incarcerated individuals receiving medication for the treatment of opioid use disorder to an appropriate provider or treatment site in the geographic region in which the individual will reside before release.
If a connection is not possible, the facility must document its efforts in the individual's record.(2) Washington state recognizes that there are multiple initiatives in place for funding treatment under this section through multiple sources including medicaid funding and waivers, criminal justice treatment account funding, and decision packages.
If a connection is not possible, the facility must document its efforts in the individual's record.NEW SECTION.  Sec.
Jurisdictions are encouraged to look towards alternative funding streams to help bridge gaps in resources, while specifically working with local county and city governments to best coordinate already established funding sources for incarcerated individuals.NEW SECTION.  Sec.
and(d) Recommendations regarding the need to add any provider types to the list of currently eligible medicaid provider types.(2) The authority must ensure only treatments that are evidence-based for the treatment of the specific acute, subacute, and chronic pain conditions will be eligible for coverage recommendations.NEW SECTION.  Sec.
and(d) Recommendations regarding the need to add any provider types to the list of currently eligible medicaid provider types.(2) The authority must ensure only treatments that are evidence-based for the treatment of the specific acute, subacute, and chronic pain conditions will be eligible for coverage recommendations.--- END ---
36.
(1) Section 15 of this act expires January 1, 2021.(2) Section 16 of this act takes effect January 1, 2021.NEW SECTION.  Sec.
37.
If specific funding for the purposes of this act, referencing this act by bill or chapter number, is not provided by June 30, 2019, in the omnibus appropriations act, this act is null and void.--- END ---
⬇ Download PDF
View plain text versions (3)

Action History

  1. House Rules "X" file.

  2. House Rules "X" file.

  3. House Rules "X" file.

  4. By resolution, reintroduced and retained in present status.

  5. By resolution, reintroduced and retained in present status.

  6. By resolution, reintroduced and retained in present status.

  7. Referred to Rules 2 Consideration.

  8. Referred to Rules 2 Consideration.

  9. Referred to Rules 2 Consideration.

  10. Placed on second reading by Rules Committee.

  11. Placed on second reading by Rules Committee.

  12. Placed on second reading by Rules Committee.

  13. Referred to Rules 2 Review.

  14. Referred to Rules 2 Review.

  15. Referred to Rules 2 Review.

  16. Scheduled for public hearing in the House Committee on Appropriations at 10:00 AM

  17. APP - Majority; 2nd substitute bill be substituted, do pass.

  18. APP - Majority; 2nd substitute bill be substituted, do pass.

  19. APP - Executive action taken by committee.

  20. APP - Majority; 2nd substitute bill be substituted, do pass.

  21. APP - Executive action taken by committee.

  22. Scheduled for public hearing in the House Committee on Appropriations at 01:30 PM

  23. Referred to Appropriations.

  24. Referred to Appropriations.

  25. Scheduled for public hearing in the House Committee on Health Care & Wellness at 08:00 AM

  26. HCW - Majority; 1st substitute bill be substituted, do pass.

  27. HCW - Majority; 1st substitute bill be substituted, do pass.

  28. Scheduled for public hearing in the House Committee on Health Care & Wellness at 01:30 PM

  29. First reading, referred to Health Care & Wellness.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 24 co-sponsors · 126 not signed on

Sponsors (1)

  • Cody

Co-sponsors (24)

Not signed on (126)

126 members have not signed on to this bill.

Show all 126 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety healthcare
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HB 1331?
HB 1331 is sponsored by Michelle Valdez (Republican), Paul Harris (Republican), Strom Peterson (Democrat), Irwin, Nicole Macri (Democrat), Mosbrucker, Laurie Jinkins (Democrat), Appleton, Cindy Ryu (Democrat), Lauren Davis (Democrat), Robinson, Carolyn Eslick (Republican), Debra Lekanoff (Democrat), My-Linh Thai (Democrat), Steve Tharinger (Democrat), Amy Walen (Democrat), Steve Bergquist (Democrat), Shelley Kloba (Democrat), Timm Ormsby (Democrat), Gerry Pollet (Democrat), Sharon Wylie (Democrat), Cody, Mari Leavitt (Democrat), Chris Kilduff (Democrat), and Monica Jurado Stonier (Democrat).
What is the current status of HB 1331?
This bill died with 2019-2020 Regular Session. It reached “Passed House” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HB 1331?
Track HB 1331 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 1331

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 1331

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →